Revance Therapeutics, Inc. reports

Company location: Nashville, TN
Fiscal year end: 31 December

Revance Therapeutics, Inc. has filed 947 SEC EDGAR filings since 23 Dec 2009

Filter by type:
10-K
10-Q
8-K
SC13D
SC13G

SEC filing history

Showing 276-300 of 946 matching filings.

Per page

25

Current page

12

424B5 File 333-250998

424B5

Filing date: 10 May 2022
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

10-Q File 001-36297

FORM 10-Q

Filing date: 10 May 2022
Reporting date: 31 Mar 2022
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

8-K File 001-36297

8-K

Filing date: 10 May 2022
Reporting date: 10 May 2022
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

4

FORM 4

Filing date: 06 May 2022
Reporting date: 04 May 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 06 May 2022
Reporting date: 04 May 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 06 May 2022
Reporting date: 04 May 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 06 May 2022
Reporting date: 04 May 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 06 May 2022
Reporting date: 04 May 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 06 May 2022
Reporting date: 04 May 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4

Filing date: 06 May 2022
Reporting date: 04 May 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

8-K File 001-36297

8-K

Filing date: 06 May 2022
Reporting date: 04 May 2022
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

8-K File 001-36297

8-K

Filing date: 21 Apr 2022
Reporting date: 21 Apr 2022
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

DEFA14A File 001-36297

DEFA14A

Filing date: 24 Mar 2022
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

DEF 14A File 001-36297

DEF 14A

Filing date: 24 Mar 2022
Reporting date: 31 Dec 2021
SEC evidence: Open document Open filing
Next action: Verify source filing

8-K File 001-36297

8-K

Filing date: 24 Mar 2022
Reporting date: 21 Mar 2022
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

8-K File 001-36297

FORM 8-K

Filing date: 21 Mar 2022
Reporting date: 18 Mar 2022
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

4

FORM 4 SUBMISSION

Filing date: 17 Mar 2022
Reporting date: 15 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4 SUBMISSION

Filing date: 17 Mar 2022
Reporting date: 15 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4 SUBMISSION

Filing date: 17 Mar 2022
Reporting date: 15 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4 SUBMISSION

Filing date: 17 Mar 2022
Reporting date: 15 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4 SUBMISSION

Filing date: 17 Mar 2022
Reporting date: 15 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

FORM 4 SUBMISSION

Filing date: 17 Mar 2022
Reporting date: 15 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

8-K File 001-36297

8-K

Filing date: 08 Mar 2022
Reporting date: 08 Mar 2022
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

S-8 File 333-263099

S-8

Filing date: 28 Feb 2022
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

10-K File 001-36297

10-K

Filing date: 28 Feb 2022
Reporting date: 31 Dec 2021
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .